Monovisc is a hyaluronan injectable medication. It is made of high molecular weight hyaluronan, which is a substance that closely resembles the synovial fluid that lubricates the joints within the body. When there is not enough synovial fluid in the joints, the cartilage in the joint suffers from wear and tear, leading to pain and swelling within the joint and causing mobility issues for the patient. Hyaluronan is naturally present in many parts of the body, making Monovisc incredibly biocompatible and safe. However, as the body ages or suffers other injuries, the body’s natural stores of hyaluronan deplete. It comes in a single-use syringe of 5mL.
What is Monovisc used for?
Monovisc is used to treat pain and swelling in the knee that is caused by osteoarthritis. Monovisc injections are typically prescribed only after other arthritis treatments are tried with little or no success. Treatments such as physical therapy and exercise, as well as pain medications such as acetaminophens will typically be the first options attempted, with Monovisc being used for patients who do not receive enough relief from these treatments. When Monovisc is injected into the knee, it replenishes lubrication and eases friction, offering patients relief from pain and increased mobility.
Side effects of Monovisc
Monovisc is a very safe and effective treatment option for patients suffering from osteoarthritis in the knees. However, it is possible for patients to have an adverse reaction to Monovisc injection, including an allergic reaction such as hives, difficulty breathing, or swelling of the face, lips, tongue, or throat. Rare and serious side effects also include bleeding, increase knee pain, and signs of infection around the knee such as warmth, swelling, or redness. If your patient has any of the aforementioned reactions, they will require medical attention. More common, mild side effects may also occur, including:
- Pain, swelling, or stiffness of the joint;
- Itching, tingling, or numbness;
- Headache or dizziness;
- Back pain;
- Swelling, pain, redness, or other discomfort at injection point.
One single-use syringe contains a 4mL dose of Monovisc. Monovisc must be directly injected into the knee joint by a healthcare provider, and treatment may include more than one Monovisc injection with a second injection administered at least 1 week after the initial injection. Patients who receive Monovisc injections can benefit from pain relief for several months before receiving more treatment.